CN1919863A - 2-aza steride framework compound and synthesis method - Google Patents

2-aza steride framework compound and synthesis method Download PDF

Info

Publication number
CN1919863A
CN1919863A CN 200610126074 CN200610126074A CN1919863A CN 1919863 A CN1919863 A CN 1919863A CN 200610126074 CN200610126074 CN 200610126074 CN 200610126074 A CN200610126074 A CN 200610126074A CN 1919863 A CN1919863 A CN 1919863A
Authority
CN
China
Prior art keywords
compound
rhcl
steride
pph
azepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200610126074
Other languages
Chinese (zh)
Inventor
麻生明
陆平
侯海荣
韦捷敏
何绮雯
陆梁华
顾振华
姜雪峰
金鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Priority to CN 200610126074 priority Critical patent/CN1919863A/en
Publication of CN1919863A publication Critical patent/CN1919863A/en
Pending legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a 2-nutrigon steroid frame compound and new synthesizing method, wherein the X in the structural formula is NR2; Y is CRR1 or NR2; R, R1 is H, nitrile radicals, COOR3 or benzene sulfinyl group and so on separately; R3 is C1-12 hydrocarbyl group, which is aromatic radical group such as alkyl group, phenyl group or naphthyl and so on.

Description

The steride framework compound and the synthetic method of one class 2-azepine
The present invention is to be ' 2005.04.14 ' applying date, and application number is ' 200510025089.8 ', and denomination of invention is divided an application for the patent of invention of ' steride framework compound, preparation method and use '.
Technical field
The present invention relates to the steride framework compound and the synthetic method of a class 2-azepine.This method has with or without compound substituent or heterocycle steroid backbone class by the cycloisomerisation reaction of duplex ene compound is synthetic with the Rh catalyzer.Itself may have certain physiologically active this compound, also can be used as synthon further synthetic have the compound of steroidal structure, these compounds may all have very strong biological activity, manyly can be used as medicine such as hormone and are widely used.
Background technology
Steroid compound extensively is present in the animal vegetable tissue, and plays an important role in vegeto-animal vital movement, and great majority have the important physical activity.Therefore, this compounds has caused numerous scientists' great interest.[((a) Nakanishi, K.in Nakanishi, K., Goto, S.; Ito, S.; Nozoe, S. (Eds.) Natural productschemistry, Vol.1, Acadenic Press:New York, N.Y., 1974, Chapter 6. (b) Dense, J.B.Steroidsand peptides, Wiley:New York, 1980.)] its very important effect is the internal hormone of organizing as the biology of live body, and steroidal has several typical classification, as: (1) anabolism class steroidal (Anabolic steroids) is used for improving the sports performance by athletes (excessively); (2) Prohormones, the precursor of real steroid hormone is provided by intravital processing factory; (3) corticosteroid (corticosteroid) influences metabolic function; (4) sexual hormoue, as androgen, oestrogenic hormon, the prostate gland hormone, therefore many alkaloids can be used for treating cancer, sacroiliitis, Sensitive disease, birth control or the like.Cholesterol (cholesterol) is one of of paramount importance steroidal, is present in the most animal cell membrane and the initiation site of various steroidal.[(Sabine, J.R.Cholesterol, Marcel Dekker, Inc.:New York, 1977.)] steroidal saponin has antimycotic, antibacterium and antiviral activity, cytotoxicity and anti-tumor activity, cardiac vascular activity.[((a) Zhou, W.S.Pure ﹠amp; Appl.Chem.1989,61,431. (b) Fung, S.; Siddal, J.B.J.Am.Chem.Soc.1980,102,6580. (c) Donaubauer, J.R.; Greaves, A.W.; McMorris, T.C.J.Org.Chem.1984,49,283.)] steroid hormone is by on the protein that is connected to acceptor, influences the function of gene transcription and cell.[((a) National Institute on Drug Abuse:Research Report series-Anabolic SteroidAbuse (see:http: (b) Hobkirk // 165.112.78.61/ResearchReports/Steroids/Anabolicsteroids. html), R. (Ed.) Steroid-biochemistry, CRC Press, Inc.:Boca Raton, Florida, 1979. (c) Baker, M.E.Evolution of adrenal and sex steroid action in vertebrates:a lignad-based mechanismmechanism for complexity.BioEssays, 25,396-400 (2003). (d) Smith, S.S.; Woolley, C.S.Cellular and molecular effects of steroid hormones on CNS excitability.Cleveland ClinicJournal of Medicine 71, supplement 2,94 (2004). (e) White, R.; Parker, M.G.Molecularmechanisms of steroid hormone action.Eudocrine-Related Cancer 5,1 (1998). (f) Marcinkowska, E.; Wiedlocha, A.steroid signal transduction activated at the cell membrane:from plants to animals.Acta Biochim.Polonica 49,735 (2002) .)] although bibliographical information is crossed the Torgov synthesis method, the Smith method, the Velluz method, biosimulation method, cycloaddition method or the like, [((a) Ananchenko, S.N.; Limanov, V.Y.; Leonov, V.N.; Rzheznikov, V.N.; Torgov, I.V., Tetrahedron 1962,18,1355. (b) Ananchenko, S.N.; Torgov, I.V., Tetrahedron Lett.1963,1553. (c) Hughes, G..A.; Smith, H.S.Chem.Ind. (London) 1960,1022. (d) Velluz, L.; Nomine, G.; Mathieu, J.Angew.Chem.1960,72,725. (e) Reihl, F.J.Prakt.Chem.1969,311,694. (f) Eder, U.; Sauer, G.; Wiechert, R.Angew.Chem.Int.Ed.1971,10,496. (g) Johnson, W.S.Bioorganic Chemistry 1978,5,51. (h) Oppolzer, W.Synthesis 1978,793. (i) Bleasdale, D.A.; Jones, D.W.J.Chem.Soc.ChemCommune.1985,1027. (j) Lachat, S.; Nayjes, F.; Overman, L.E.Tetrahedron 1994,50,347, (k) Couturier, M.; Deslongchamps, P.Synlett, 1996,1140. (l) Stork, G.; Weat, F.; Lee, Y.; Isaacs, R.C.A.; Manabe, S.J.Am.Chem.Soc.1996,118,10660. (m) Overman, L.F.; Rucker, P.V.Tetrahedron Lett.1998,39,4643. (n) Tietze, L.F.; Nobel, T.; Spescha, M.Angew.Chem.Int.Ed, Engl.1996,35,2259.)] but Shang Weiyou reported the cycloisomerisation by Rh catalysis duplex ene compound obtains the reaction of steroid backbone.
Summary of the invention
The purpose of this invention is to provide the steride framework compound of the new class 2-azepine of a class, promptly have compound with or without substituent heterocycle steroid backbone class.
The object of the invention provides a kind of synthetic a kind of method with steride framework compound of above-mentioned steroid one class 2-azepine of cycloisomerisation reaction by the duplex ene compound.
The structural formula that has with or without the compound of the steroid backbone class of substituent 2-azepine of the present invention is:
Figure A20061012607400051
Wherein, X is NR 2, Y is CRR 1Or NR 2Wherein, R, R 1Be respectively H, itrile group, COOR 3, or benzenesulfinyl etc., wherein R 3Be C 1-12Alkyl, R 2Be p-toluenesulfonyl (Ts), H or C 1-12Alkyl, described alkyl is aromatic groups such as alkyl, phenyl or naphthyl.
The invention provides a kind of synthetic a kind of novel method of cycloisomerisation reaction with compound of steroid backbone class by the duplex ene compound.Reaction formula is as follows:
Method of the present invention: in a reactor, add the Rh catalyzer, to have with or without substituent heteroatomic duplex vinyl compound and be dissolved in the solvent, stir, in suitable temperature, suitable time internal reaction obtains having with or without compound substituent or heterocycle steroid backbone class, promptly
Figure A20061012607400053
The duplex vinyl compound and the mol ratio of catalyzer be respectively 1: 0.8～1.2: 0.005～0.5, recommend mol ratio to be: 1: 1: 0.01～0.05 reacts.
Wherein used Rh catalyzer can be RhCl (CO) (PPh 3) 2, [RhCl (cod)] 2+ phosphorus part, RhCl (PPh 3) 3, RhH (CO) (PPh 3) 2, [RhCl (CO) 3] 2, [Rh (cod) 2] BF 4Or the like.Wherein cod is 1,5 cyclooctadiene, and the phosphorus part can be triphenyl phosphorus, trialkyl phosphorus, and alkyl can be C 1～C 8Alkyl chain length, or aromatic groups such as phenyl, benzyl.The phosphorus part is triphenylphosphinc oxide, three (C 1-8Alkoxyl group) phosphorus, triphenylphosphinc oxide or tribenzyl oxygen phosphorus.
Reaction solvent is conventional organic solvent, as toluene, normal hexane, hexanaphthene, tetrahydrofuran (THF), methylene dichloride, trichloromethane, dimethyl sulfoxide (DMSO), N, dinethylformamide, N,N-dimethylacetamide, dimethylbenzene, 1,4-dioxane, acetonitrile, methyl alcohol, ethanol etc.; Temperature of reaction is that room temperature arrives reflux temperature; Reaction times is 0.5～40 hour.
The present invention is catalyzer with Rh, has the compound that has steroidal class skeleton with or without the cycloisomerisation reaction one-step synthesis of substituent or heteroatomic duplex ene compound by catalysis.This method is simple to operate, is a kind of method easily and effectively.Have following characteristics: (1) raw material conveniently is easy to get, and is simple to operate, and one goes on foot promptly convenient post-treatment.(2) reaction yield is higher.(3) conversion unit is simple, is easy to suitability for industrialized production.
Embodiment
Following examples help to understand the present invention, but are not limited to content of the present invention:
Embodiment 1
Different solvents
entry Catalyzer Solvent (ml) Temperature (℃) Time (h) Productive rate (%)
1 2 3 4 RhCl(CO)(PPh 3) 2 RhCl(CO)(PPh 3) 2 RhCl(CO)(PPh 3) 2 RhCl(CO)(PPh 3) 2 Methylene dichloride tetrahydrofuran (THF) acetonitrile dimethylbenzene Room temperature 80 60 130 32 28 30 0.5 58 48 35 35
Different catalysts
entry Catalyzer Toluene (ml) Temperature (℃) Time (h) Productive rate (%)
1 2 3 4 5 RhCl(CO)(PPh 3) 2 [RhCl(cod)] 2+PPh 3 RhCl(PPh 3) 3 [RhCl(cod)] 2+P(OPh) 3 RhH(CO)(PPh 3) 2 1 2 2 4 6 110 110 110 110 110 2 0.8 3 12.5 18 48 48 30 45 41
Recommend
Figure A20061012607400062
In the exsiccant reaction tubes, add 1a (59mg, 0.25mmol), catalyzer RhCl (CO) (PPh 3) 2(2mg, 0.003mmol) and 6ml toluene, TLC follows the tracks of reaction to finishing, be spin-dried for solvent, directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2a 43mg (73%) to column chromatography, white solid, fusing point .124-126 ℃ (sherwood oil, ethyl acetate); The hydrogen spectrum 1H NMR (300MHz, CDCl 3): 5.38 (bs, 1H), 4.79 (s, 1H), 4.75 (s, 1H), 3.75 (s, 3H), 3.73 (s, 6H), 3.67 (s, 3H), 3.03-2.75 (m, 3H), 2.70-2.00 (m, 12H), 1.85-1.75 (m, 1H), 1.52 (t, J=13.5Hz, 1H); The carbon spectrum 13C NMR (75.4MHz, CDCl 3): 30.5,30.7,31.3,32.3,32.5,37.4,37.9,38.9,45.3,46.7,52.6,52.7,52.75,52.82,53.6,59.7,108.6,116.4,129.1,130.7,137.7,145.5,171.4,172.1,172.6,172.9; Infrared IR (KBr) 2929,2901,1748,1733,1451,1437cm -1Mass spectrum EIMS: mass-to-charge ratio (%): 472 (M +, 12.79), 145 (100); Ultimate analysis calculated value C 26H 32O 8: (%) C 66.09, and H 6.83; Measured value: C 66.08, H 6.92.
Embodiment 2
Figure A20061012607400071
In the exsiccant reaction tubes, add 1a ' (87mg, 0.25mmol), catalyzer RhCl (CO) (PPh 3) 2(1mg, 0.002mmol) and 4ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, and directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2a ' 55mg (64%) to column chromatography
Infrared IR (KBr) 2936,2920,1756,1740,1457,1436cm -1Mass spectrum MALDI:m/z (%): 735 (M ++ K), 719 (M ++ Na); High resolution mass spectrum HRMS calculated value C 46H 40O 8Na +[M ++ Na], 719.4499; Measured value, 719.4590.
Embodiment 3
Figure A20061012607400081
In the exsiccant reaction tubes, add 1a " (180mg, 0.25mmol), catalyzer RhCl (CO) (PPh 3) 2(1mg, 0.002mmol) and 4ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, directly column chromatography (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2a " 104mg (58%).
Infrared IR (KBr) 2933,2915,1750,1744,1459,1440,750,710cm -1Mass spectrum MALDI:m/z (%): 759 (M ++ K), 743 (M ++ Na); High resolution mass spectrum HRMS calculated value C 46H 40O 8Na +[M ++ Na], 743.2621; Measured value, 743.2690.
Embodiment 4
Figure A20061012607400082
In the exsiccant reaction tubes, add 1b (43mg, 0.25mmol), catalyzer RhCl (CO) (PPh 3) 2(1mg, 0.002mmol) and 4ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, and directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2b 32mg (74%), white solid, fusing point .144-146 ℃ (ether) to column chromatography; Hydrogen spectrum data 1H NMR (300MHz, CDCl 3): 5.42 (bs, 1H), 4.96 (s, 1H), 4.92 (s, 1H), 3.23-3.02 (m, 2H), 2.98-2.55 (m, 8H), 2.42-2.10 (m, 5H), 2.02-1.88 (m, 1H), 1.85 (t, J=12.3Hz, 1H); Carbon spectrum data 13C NMR (75.4MHz, CDCl 3): 30.3,30.4,31.0,31.8,32.3,33.8,34.3,37.1,41.6,42.7,44.7,46.1,111.9,113.6,115.2,116.1,116.3,116.4,128.5,130.5,138.2,140.7; Infrared IR (KBr) 3073,2938,2912,2250,1654,1455,1444cm -1Mass spectrum EIMS:m/z (%): 340 (M +, 100); High resolution mass spectrum HRMS calculated value C 22H 20N 4Na +[M ++ Na], 363.1580; Measured value, 363.1594.
Embodiment 5
Figure A20061012607400091
In the exsiccant reaction tubes, add 1c (1.509g, 3.76mmol), catalyzer RhCl (CO) (PPh 3) 2(260mg, 0.38mmol) and the dried toluene of 90ml, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, and directly (methylene dichloride: purifying methyl alcohol=8: 1) obtains compound 2c1.086g (72%), white solid to column chromatography.Fusing point .143-145 ℃ (methylene dichloride, ether); The hydrogen spectrum 1H NMR (300MHz, CDCl 3): 8.18-7.86 (m, 8H), 7.72-7.35 (m, 12H), 4.91 (bs, 1H), 4.75 (s, 1H), 4.71 (s, 1H), 3.02-2.50 (m, 9H), 2.42-2.20 (m, 3H), 2.15-1.90 (m, 4H), 1.70-1.62 (m, 1H); The carbon spectrum 13C NMR (75.4MHz, CDCl 3): 26.1,28.5,30.2,30.5,31.9,34.3,36.1,37.5,46.4,47.4,87.9,93.5,110.7,114.1,126.9,128.56,128.63,128.7,128.8,131.0,131.2,131.36,131.39,131.40,131.5,134.3,134.50,134.55,135.8,136.0,136.4,136.7,139.8,142.3; Infrared IR (KBr) 3066,2906,1447,1328,1309,1144cm -1Mass spectrum MALDI:m/z (%): 839 (M ++ K), 823 (M ++ Na); High resolution mass spectrum HRMS calculated value C 42H 40O 8S 4Na +[M ++ Na], 823.1498; Measured value, 823.1497.
Embodiment 6
Figure A20061012607400092
In the exsiccant reaction tubes, add 1d (54mg, 0.25mmol), catalyzer RhCl (CO) (PPh 3) 2(9mg, 0.013mmol) and 6ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, and directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2d 36mg (67%), white liquid, hydrogen spectrum to column chromatography 1H NMR (300MHz, CDCl 3): 5.39 (bs, 1H), 4.87 (s, 1H), 4.82 (s, 1H), 4.35-4.18 (m, 4H), 3.22-1.50 (m, 17H), 1.39-1.25 (m, 6H); Infrared IR (neat) 2983,2908,2242,1743,1653,1447cm -1Mass spectrum MALDI:m/z (%): 434 (M -, 100); High resolution mass spectrum HRMS calculated value C 26H 30N 2O 4Na +[M ++ Na], 457.2098; Measured value, 457.2109.
Embodiment 7
In the exsiccant reaction tubes, add 1f (69mg, 0.25mmol), catalyzer RhCl (CO) (PPh 3) 2(2mg, 0.003mmol) and 6ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, and directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound white solid 2f 39mg (67%), fusing point .85-86 ℃ (methylene dichloride, ether) to column chromatography; The hydrogen spectrum 1H NMR (300MHz, CDCl 3): 7.61 (d, J=8.7Hz, 2H), 7.52 (d, J=8.7Hz, 2H), 7.31 (d, J=7.8Hz, 2H), 7.02 (d, J=8.1Hz, 2H), 5.23-4.98 (m, 1H), and 4.78-4.71 (m, 2H), 3.98-3.88 (m, 2H), 3.25-3.09 (m, 3H), and 3.29-2.95 (m, 2H), 2.90-2.63 (m, 3H), 2.58-2.40 (m, 2H), 2.39-2.30 (m, 4H), 2.18 (s, 3H), 2.16-1.90 (m, 2H), 1.76 (t, J=11.1Hz, 1H), 1.74-1.62 (m, 1H); The carbon spectrum 13C NMR (75.4MHz, CDCl 3): 21.4,21.5,29.7,29.8,30.3,32.2,40.4,44.8,46.4,46.5,49.5,50.5,111.0,115.0,127.4,127.6,127.7,129.3,129.4,129.8,133.1,133.5,136.8,140.9,143.2,143.8; Infrared IR (KBr) 3062,2903,2846,1652,1597,1344cm -1Mass spectrum MALDI:m/z (%): 589 (M ++ K), 573 (M ++ Na), 551 (M ++ H); High resolution mass spectrum HRMS calculated value C 30H 35N 2O 4S 2 +[M ++ 1], 551.2033; Measured value, 551.2037.
Embodiment 8
In the exsiccant reaction tubes, add 1f (413mg, 1.5mmol), 1a (357mg, 1.5mmol) catalyzer RhCl (CO) (PPh 3) 2(207mg, 0.3mmol) and 72ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2a 106mg (30%), 2f, 82mg (20%) to column chromatography, 2af 68mg (9%), 2fa 88mg (12%), 2fa: 1H NMR (300MHz, deuterochloroform) δ 7.66 (d, J=8.0Hz, 2H), 7.31 (d, J=8.0Hz, 2H), 5.29 (d, J=2.1Hz, 1H), 4.77 (d, J=8.7Hz, 2H), 3.90-4.10 (m, 2H), 3.72 (s, 3H), 3.58-3.80 (m, 2H), 3.50 (s, 3H), 3.00-3.12 (d, J=14.4Hz, 1H), 2.65-2.97 (m, 2H), 2.30-2.65 (m, 4H), 2.40 (s, 3H), 1.85 (m, 5H), 1.73-1.84 (m, 1H); 13C NMR (75.4MHz, deuterochloroform) δ 172.6,172.1,144.6,143.5,137.5,133.3,132.4,129.7,127.6,126.4,114.9,109.2,59.6,52.9,52.4,46.5,46.4,44.94,44.86,40.3,38.9,37.9,32.4,30.4,30.1,21.5; MS (ESI) m/z 512 (M ++ H), 529 (M ++ NH 4); IR (neat) 1733,1346,1165cm -1.HRMS calculated value C 28H 33NO 6SNa:534.1921. measured value: 534.1923.2af solid, mp 157-160 ℃ (ethane/ethyl acetate); 1H NMR (300MHz, deuterochloroform) δ 7.66 (d, J=8.5Hz, 2H), 7.28 (d, J=8.5Hz, 2H), 5.30-5.35 (m, 1H), 4.75 (d, J=1.8Hz, 2H), 3.73 (s, 3H), 3.72 (s, 3H), 3.20-3.40 (m, 3H), 3.11 (t, J=9.3Hz, 1H), and 2.75-3.00 (m, 3H), 2.45-2.65 (m, 3H), and 2.35-2.45 (m, 1H), 2.44 (s, 3H), and 2.25-2.35 (m, 1H), 2.10-2.18 (m, 1H), and 1.90-2.05 (m, 1H), 1.63-1.85 (m, 2H), 1.30 (t, J=13.5Hz, 1H); 13C NMR (75.4MHz, deuterochloroform) δ 172.4,171.2,143.3,141.7,136.9,133.7,130.2,129.5,127.7,127.5,116.6,110.4,53.5,52.8,52.7,50.7,49.6,46.5,45.0,37.3,32.4,32.3,31.2,30.4,30.3,21.5; MS (ESI) m/z 512 (M ++ H); IR (neat) 1760,1728,1346,1161cm -1. ultimate analysis. calculated value C 28H 33NO 6S:C 65.73; H 6.50; N2.74.Found:C 65.69; H 6.42; N 2.69.
Embodiment 9
Figure A20061012607400111
In the exsiccant reaction tubes, add 1f (413mg, 1.5mmol), 1b (255mg, 1.5mmol) catalyzer RhCl (CO) (PPh 3) 2(108mg, 0.075mmol) and 72ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2b 84mg (33%), 2f, 76mg (18%) to column chromatography, 2bf 57mg (9%), 2fb 88mg (14%), 2fb 1H NMR (300MHz, deuterochloroform) δ 7.66 (d, J=8.1Hz, 2H), 7.32 (d, J=8.1Hz, 2H), 5.36 (d, J=1.8Hz, 1H), 4.92 (d, J=4.2Hz, 2H), 4.08 (dd, J=11.1,5.4Hz, 1H), 4.00 (dd, J=16.2,2.7Hz, 1H), 2.95-3.22 (m, 3H), 2.50-2.95 (m, 6H), 2.42 (s, 3H), and 1.95-2.35 (m, 5H), 1.75-1.87 (m, 1H); 13C NMR (75.4MHz, deuterochloroform) δ 143.6,141.1,136.3,133.2,130.5,129.7,127.9,127.4,116.4,116.2,115.7,111.7,46.2,45.6,44.8,44.5,43.1,41.8,40.4,32.3,32.0,30.2,29.9,21.5; MS (ESI) m/z 446 (M ++ H); IR (level and smooth peak) 1345,1162cm -1.HRMS calculated value C 26H 27N 3O 2SNa:468.1716. measured value: 468.1714.2bf solid, mp 213-216 ℃ (ethane/acetic acid ethyl ester); 1H NMR (300MHz, deuterochloroform) δ 7.69 (d, J=8.4Hz, 2H), 7.31 (d, J=8.4Hz, 2H), 5.35-5.42 (m, 1H), 4.80 (d, J=6.3Hz, 2H), 3.10-3.40 (m, 4H), and 2.47-3.10 (m, 8H), 2.44 (s, 3H), and 1.97-2.35 (m, 3H), 1.80-1.90 (m, 1H), 1.60 (t, J=12.3Hz, 1H); 13C NMR (75.4MHz, deuterochloroform) δ 143.3,140.8,138.6,133.6,129.7,129.5,128.1,127.5,116.2,115.1,113.0,111.0,50.8,49.3,46.3,44.6,36.9,34.8,33.8,32.0,31.1,30.33,30.29,21.5; MS (ESI) m/z 446 (M ++ H); IR (level and smooth peak) 1344,1159cm -1. ultimate analysis. calculated value C 26H 27N 3O 2S:C 70.08; H 6.11; N 9.43. measured value: C 70.11; H 6.04; N 9.38.
Embodiment 10
In the exsiccant reaction tubes, add 1f (413mg, 1.5mmol), 1c (255mg, 1.5mmol) catalyzer RhCl (CO) (PPh 3) 2(108mg, 0.075mmol) and 72ml toluene, TLC follows the tracks of reaction to finishing, and is spin-dried for solvent, directly (sherwood oil: ethyl acetate=8: 1) purifying obtains compound 2c 74mg (25%), 2f to column chromatography, 49mg (24%), 2cf 74mg (15%), 2fc 37mg (7%) .2fc 1H NMR (300MHz, deuterochloroform) δ 8.06 (d, J=7.5Hz, 2H), 7.89 (d, J=7.5Hz, 2H), 7.40-7.80 (m, 8H), 7.30 (d, J=7.8Hz, 2H), 5.34 (s, 1H), 4.82 (s, 2H), and 3.90-4.20 (m, 2H), 3.00-3.17 (m, 2H), 2.67-3.00 (m, 4H), 2.27-2.67 (m, 4H), 2.37 (s, 3H), and 2.00-2.37 (m, 4H), 1.70-1.85 (m, 1H); 13C NMR (75.4MHz, deuterochloroform) δ 143.5,142.4,137.1,136.8,136.0,134.7,134.4,133.7,131.7,131.3,130.9,129.7,128.8,128.6,127.5,125.7,115.1,110.8,47.0,46.3,45.8,44.8,40.6,36.0,34.9,31.8,30.4,30.0,21.5; MS (ESI) m/z 676 (M ++ H); IR (level and smooth peak) 1329,1310,1158,1144cm -1.HRMS calculated value C 36H 37NO 6S 3Na:698.1675. measured value: 698.1673.2cf 1H NMR (300MHz, deuterochloroform) δ 8.13 (d, J=7.2Hz, 2H), 8.99 (d, J=7.2Hz, 2H), 7.50-7.75 (m, 8H), 7.30 (d, J=9.6Hz, 2H), 5.20 (s, 1H), 4.73 (s, 2H), and 3.23-3.41 (m, 2H), 2.58-3.18 (m, 10H), 2.42 (s, 3H), 2.25-2.40 (m, 2H), 1.95-2.10 (m, 2H), 1.82 (dd, J=13.8,12.3Hz, 1H); 13C NMR (75.4MHz, deuterochloroform) δ 143.4,141.3,137.7,136.8,135.9,134.73,134.67,133.6,131.5,131.1,129.7,129.3,128.9,128.8,128.6,127.4,115.4,110.6,50.6,49.6,46.5,44.6,36.7,32.5,30.7,39.7,29.5,28.9,26.3,21.5; MS (ESI) m/z 676 (M ++ H); IR (level and smooth peak) 1332,1309,1146cm -1.HRMS calculated value C 36H 37NO 6S 3Na:698.1675. measured value: 698.1675.

Claims (5)

  1. The steride framework compound of 1, one class 2-azepine is the compound that has with or without substituent heterocycle steroid backbone class, and its structural formula is as follows:
    Figure A2006101260740002C1
    X is NR 2, Y is CRR 1Or NR 2Wherein, R, R 1Be respectively H, itrile group, COOR 3, or benzenesulfinyl, wherein R 3Be C 1-12Alkyl, R 2Be p-toluenesulfonyl, H or C 1-12Alkyl, described alkyl is alkyl, phenyl or naphthyl.
  2. 2, a kind of synthetic method of compound of steroid backbone class of 2-azepine as claimed in claim 1, it is characterized in that in organic solvent and room temperature to reflux temperature, structural formula is respectively:
    Figure A2006101260740002C2
    The mol ratio of duplex vinyl compound and Rh catalyzer is reaction in 1: 0.8～1.2: 0.005～0.5 o'clock 0.5～40 hour,
    Wherein X and Y are according to claim 1.
  3. 3, the synthetic method of the steride framework compound of 2-azepine as claimed in claim 2 is characterized in that described Rh catalyzer is RhCl (CO) (PPh 3) 2, [RhCl (cod)] 2+ phosphorus part, RhCl (PPh 3) 3, RhH (CO) (PPh 3) 2, [RhCl (CO) 3] 2Or [Rh (cod) 2] BF 4Wherein cod is 1,5 cyclooctadiene; The phosphorus part is triphenyl phosphorus, three (C 1-8Alkoxyl group) phosphorus, triphenylphosphinc oxide or tribenzyl oxygen phosphorus.
  4. 4, the synthetic method of the steride framework compound of 2-azepine as claimed in claim 2, it is characterized in that described organic solvent is toluene, normal hexane, hexanaphthene, tetrahydrofuran (THF), methylene dichloride, trichloromethane, dimethyl sulfoxide (DMSO), N, dinethylformamide, N, N-N,N-DIMETHYLACETAMIDE, 1,4-dioxane, acetonitrile, methyl alcohol or ethanol.
  5. 5, the synthetic method of the steride framework compound of 2-azepine as claimed in claim 2 is characterized in that described structural formula is:
    Figure A2006101260740002C3
    The duplex vinyl compound and the mol ratio of Rh catalyzer be respectively 1: 1: 0.01～0.05.
CN 200610126074 2005-04-14 2005-04-14 2-aza steride framework compound and synthesis method Pending CN1919863A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200610126074 CN1919863A (en) 2005-04-14 2005-04-14 2-aza steride framework compound and synthesis method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200610126074 CN1919863A (en) 2005-04-14 2005-04-14 2-aza steride framework compound and synthesis method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100250898A Division CN1298730C (en) 2005-04-14 2005-04-14 Steroid framework compound, synthesizing process and its use

Publications (1)

Publication Number Publication Date
CN1919863A true CN1919863A (en) 2007-02-28

Family

ID=37777736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200610126074 Pending CN1919863A (en) 2005-04-14 2005-04-14 2-aza steride framework compound and synthesis method

Country Status (1)

Country Link
CN (1) CN1919863A (en)

Similar Documents

Publication Publication Date Title
US8501980B2 (en) Process for producing oseltamivir phosphate and intermediate compound
JP2014534183A (en) Method for isolating ingenol
Kiss et al. Substrate-dependent fluorinations of highly functionalized cycloalkanes
CN1298730C (en) Steroid framework compound, synthesizing process and its use
US8039626B2 (en) Method of manufacturing of 7-ethyl-10-hydroxycamptothecin
CN1919863A (en) 2-aza steride framework compound and synthesis method
CN111018901B (en) Zanamivir and ranamivir intermediate and synthesis method thereof
KR101102957B1 (en) Asymmetric synthetic method of preparing ?-dihydrotetrabenazine and tetrabenazine
US7119213B2 (en) Pharmacologically active isolated or purified dauer pheromone compound for controlling aging and stress and method for isolating and characterizing the same
WO2007070238A3 (en) Processes for the preparation of modafinil and analogs thereof
Di Bussolo et al. Aminolysis of glycal-derived allyl epoxides and activated aziridines. Effects of the absence of coordination processes on the regio-and stereoselectivity
JP4770032B2 (en) Sheatan derivative
CN110627852B (en) Biotin-labeled naringin, preparation method and application thereof
Stepanov et al. Stereocontrolled synthesis of (+)-and (−)-iridomyrmecin from citronellene enantiomers
Lloyd Alkaloids of Ormosia jamaicensis (Urb.). The Structure of Jamaidine and Jamaicensine.
CN112679484B (en) Preparation method of chiral intermediate and chiral isomer of neuraminidase inhibitor
Belykh et al. Transformations of the extra ring in pheophorbide a methyl ester in the reaction with N, N, N′, N′-tetramethylmethanediamine
CN110698533B (en) Ursolic acid indoquinone derivative and preparation method and application thereof
Chandrasekhar et al. One pot synthesis of acetylated homoallyl alcohols
RU2351604C1 (en) Method of producing 2,3-monoacetonide 20-hydroxyecdysone
Pandey et al. Enantioselective synthesis of (-)-(5R, 6S)-6-acetoxyhexadecan-5-olide via tandem α-aminooxylation-Henry reaction
WO1992001691A1 (en) New derivatives of streptogramines and preparation thereof
EP1951654A1 (en) Improved process for oseltamivir phosphate
JPWO2003080561A1 (en) Manufacturing method of voglibose
CN114105790A (en) Preparation method of 3-amino-4, 5-dibromobenzoic acid methyl ester

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070228